-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After breakthroughs in the R&D and industrialization of the microsphere technology platform, the commercialization process of the first microsphere product, Recinto®, is also accelerating
.
Only more than 40 days after it was approved for marketing on January 12, 2021, Recinto® has begun to supply medicines to many provinces and cities across the country
.
In addition, in order to benefit more patients around the world, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe
.
"The listing of Recinto® is of great significance.
It confirms our long-term commitment to provide innovative treatment solutions around the needs of patients; it is also our microsphere technology platform to achieve breakthrough results from 0 to 1.
, To promote the platform to accelerate the launch of more innovative microsphere preparations and serve more patients
.
” Yang Rongbing said
.
In addition to the marketed Rexinto®, Luye Pharma’s innovative microsphere platform will continue to leverage its core technology advantages and have a deep layout in the field of major diseases such as tumors and central nervous system.
A series of microsphere products in different stages of research and development include: treatment of Parkinson's Rotigotine sustained-release microspheres for injection (LY03003) for the treatment of disease, goserelin acetate sustained-release microspheres for injection (LY01005) for the treatment of prostate cancer, breast cancer and other sex hormone-dependent diseases, treatment of Parkinson’s disease, restlessness High-quality innovative drugs such as LY03009 for leg syndrome
.
Subsequent new drugs will form a rich product portfolio with Recinto®, leverage the company's superior strength in this technical field, and bring new high-quality treatment options to patients
.
